Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.49 |
| ▸ | SMO | Q99835 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672609 | 0.93 | CCR1 (0.50) | CCR1SMOALDH1A1MAPTMAPK14 | |
| SCHEMBL4670233 | 0.91 | ALDH1A1 (0.56) | SMOALDH1A1MAPTMAPK14GAA | |
| SCHEMBL4670702 | 0.85 | ALDH1A1 (0.56) | SMOALDH1A1MAPTMAPK14GAA | |
| SCHEMBL4670706 | 0.85 | CCR1 (0.53) | CCR1SMOALDH1A1MAPTMAPK14 | |
| SCHEMBL4672311 | 0.79 | ALDH1A1 (0.47) | SMOALDH1A1MAPTMAPK14GAA | |
| SCHEMBL2862091 | 0.77 | ALDH1A1 (0.53) | CCR1ALDH1A1MAPTMAPK14GAA | |
| SCHEMBL4673186 | 0.77 | CCR1 (0.53) | CCR1SMOALDH1A1MAPTMAPK14 | |
| SCHEMBL2852107 | 0.76 | CCR1 (0.83) | CCR1MAPTGAAHPGD | |
| SCHEMBL2850622 | 0.75 | ALDH1A1 (0.57) | CCR1ALDH1A1MAPTMAPK14GAA | |
| SCHEMBL3971476 | 0.74 | ALDH1A1 (0.58) | ALDH1A1MAPTMAPK14GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397341-B1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | disclosed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | disclosed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | SERPINC1, F11, SERPINE1 | CCR1 106/4885SMO 2287/4885ALDH1A1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.